Poor Performance of Rapid Molecular Tests to Define Eligibility for the Shortcourse Multidrug-resistant Tuberculosis Regimen.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 30239638.
- Also identified by DOI 10.1093/cid/ciy808.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The World Health Organization recommends shortcourse regimen (SCR) to treat multidrug resistant tuberculosis for patients with strains susceptible by line-probe assays (LPAs) to second-line drugs. Our retrospective study shows LPAs have suboptimal specificity in predicting eligibility for SCR; a quarter of eligible patients would receive inadequate therapy with SCR.
Medical subject headings
- Antitubercular Agents
- Microbial Sensitivity Tests
- Molecular Typing
- Tuberculosis, Multidrug-Resistant